Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsDividends payablesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

PharmaCyte Biotech (PMCB) Retained Earnings (2016 - 2026)

PharmaCyte Biotech (PMCB) has disclosed Retained Earnings for 15 consecutive years, with -$100.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings fell 7.55% to -$100.7 million in Q4 2025 year-over-year; TTM through Oct 2025 was -$100.7 million, a 7.55% decrease, with the full-year FY2025 number at -$23869.0, down 1.52% from a year prior.
  • Retained Earnings was -$100.7 million for Q4 2025 at PharmaCyte Biotech, down from -$93.3 million in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of -$14453.0 in Q3 2022 to a low of -$119.1 million in Q3 2023.
  • A 5-year average of -$42.2 million and a median of -$23419.5 in 2024 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: tumbled 824241.45% in 2023, then skyrocketed 99.98% in 2024.
  • PharmaCyte Biotech's Retained Earnings stood at -$109.4 million in 2021, then fell by 5.17% to -$115.1 million in 2022, then decreased by 1.11% to -$116.4 million in 2023, then rose by 19.49% to -$93.7 million in 2024, then fell by 7.55% to -$100.7 million in 2025.
  • Per Business Quant, the three most recent readings for PMCB's Retained Earnings are -$100.7 million (Q4 2025), -$93.3 million (Q3 2025), and -$23869.0 (Q2 2025).